系列问答134——罗格列酮是否增加心血管事件风险,如何安全使用管理?

原文传递

导出

作者本刊编辑部

出处《药物不良反应杂志》 2010年第5期376-376,共1页 Adverse Drug Reactions Journal

关键词心血管事件罗格列酮死亡风险安全使用管理噻唑烷二酮类胰岛素敏感性 NISSEN

参考文献7

1Nissen SE and Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[EB/OL].N Engl J Med,2007;DOI 10.1056/NEJMoa072761.(2007-06-14).[2010-10-25].http://www.nejm.org.
2Home PD,Pocock SJ,Beck-Nielsen H,et al.Resiglitazone evaluated for cardiovascular outcomes-an interim analysis[EB/OL].N Engl J Med,June 5,2007;DOI 10.1056/NEjMoa073394.(2007-06-05).[2010-10-25].http://www.nejm.org.
3Lipscombe LL,Comes T,Lévesque LE,et al.Thiazolidinediones and cardiovascular outcomes in older patients with diabetes[J].JAMA,2007,298(22):2634-2643.
4Nissen SE,Woiski K.Rosiglitazone Revisited:An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality[J].Arch Intern Med,2010,170(14):1191-1201.
5Graham DJ,Ouellet-Hellstrom R,MaCurdy TE,et al.Risk of acute myocardial infarction,stroke,heart failure,and death in elderly Medicare patients treated with rosiglitazone or pioglitazone[J].JAMA,2010,304(4):411-418.
6EMA.Press release:European Medicines Agency recommends suspension of Avandia,Avandamet and Avaglim[EB/OL].(2010-09-23).[2010-10-25].http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true.
7FDA.Avandia(rosiglitazone):REMS-Risk of Cardiovascular Events[EB/OL].(2010-09-23).[2010-10-25].http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226994.htm.

药物不良反应杂志

2010年第5期

内容加载中请稍等...